2SPD-033 Evaluation of docetaxel in low and high burden metastatic hormone sensitive prostate cancer

Abstract

According to the delta values, there could be clinically relevant differences among them. Conclusion and relevance NMA showed no significant differences in OS between PC-pembrolizumab and carboplatin-gemcitabine, PC-motesanib, PC-necitumumab, PC-olaratumab and pembrolizumab in umSNSCLC, but there could be clinically relevant differences.